Patent: 10,005,779
✉ Email this page to a colleague
Summary for Patent: 10,005,779
| Title: | 1\',4\'-thio nucleosides for the treatment of HCV |
| Abstract: | Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1\',4\'-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: ##STR00001## or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, R.sup.A, R.sup.B, W, X, Y, and Z are as described herein. |
| Inventor(s): | Dukhan; David (Saint Gely du Fesc, FR), Gosselin; Gilles (Montpellier, FR), Dousson; Cyril B. (Canet, FR) |
| Assignee: | IDENIX PHARMACEUTICALS LLC (Cambridge, MA) |
| Application Number: | 14/296,122 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,005,779
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
| Kadmon Pharmaceuticals Llc | INFERGEN | interferon alfacon-1 | Injection | 103663 | 10/06/1997 | ⤷ Try a Trial | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
